



# UNITED STATES PATENT AND TRADEMARK OFFICE

mg

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/682,199	10/10/2003	Peter Hermentin	06478.1495	1253

22852 7590 11/19/2007  
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER  
LLP  
901 NEW YORK AVENUE, NW  
WASHINGTON, DC 20001-4413

EXAMINER
----------

VENCI, DAVID J

ART UNIT	PAPER NUMBER
----------	--------------

1641

MAIL DATE	DELIVERY MODE
-----------	---------------

11/19/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



UNITED STATES PATENT AND TRADEMARK OFFICE

---

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

Application Number: 10/682,199  
Filing Date: October 10, 2003  
Appellant(s): HERMENTIN ET AL.

---

Elizabeth A. Doherty  
Reg. No. 50,894

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP  
901 New York Avenue, NW  
Washington, D.C. 20001-4413

For Appellant

**EXAMINER'S ANSWER**

This is in response to the Appeal Brief filed August 10, 2007, appealing from  
the Office action mailed November 29, 2006.

Art Unit: 1641

**(1) Real Party in Interest**

The Appeal Brief identifies "CSL Behring GmbH" as the Real Party in interest.

**(2) Related Appeals and Interferences**

Examiner is not aware of any related appeals, interferences, or judicial proceedings affecting, directly affected by, or having a bearing on the Board's decision in the pending appeal.

**(3) Status of Claims**

The Appeal Brief correctly identifies claims 16-25, 27, 28, 30, 31, 33 and 25 under appeal.

**(4) Status of Amendments After Final**

The Appeal Brief identifies Appellants' amendment after final rejection filed February 22, 2007, which was entered March 21, 2007.

**(5) Summary of Claimed Subject Matter**

The Appeal Brief correctly summarizes the claimed subject matter.

**(6) Grounds of Rejection to be Reviewed on Appeal**

The Appeal Brief correctly identifies the rejections to be reviewed on appeal.

**(7) Claims Appendix**

The copy of the appealed claims in the Claims Appendix to the Appeal Brief is correct.

**(8) Evidence Relied Upon**

Shainoff, J.R. *Electrophoresis and Direct Immunoprobng on Glyoxyl Agarose and Polyacrylamide Composites*, in ADVANCES IN ELECTROPHORESIS, Chrambach, Dunn & Radola, Eds., VCH Publishers, New York, Vol. 6, pp. 65-176 (1993).

Bhat, S.P. & Nagineni, C.N. Use of "Submarine" Gel Electrophoresis for Running Multiple Two-Dimensional Protein Gels. ANAL. BIOCHEM. 1988;170:105-109.

Art Unit: 1641

Perrella, M. & Denisov, I. Low-Temperature Electrophoresis Methods. METHODS ENZYMOL. 1995;259:468-487.

### **(9) Grounds of Rejection**

The following grounds of rejection are applicable to the appealed claims:

#### *Claim Rejections - 35 USC § 103*

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness<sup>1,2</sup> rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 16-24, 27-28, 30-31, 33 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shainoff, *Electrophoresis and direct immunoprobng on glyoxal agarose*, in ADVANCES IN ELECTROPHORESIS, Vol. 6, VCH Publishers, pp. 65-176 (1993), in view of Bhat & Nagineni, 170 ANAL. BIOCHEM 105 (1988).

Shainoff teaches a method for the determination of multimers of multimer-forming proteins by gel electrophoresis, comprising:

fractionating a sample containing von Willebrand factor<sup>3</sup> or fibrinogen<sup>4</sup> into multimer bands by electrophoresis using a continuous,<sup>5</sup> homogeneous<sup>6</sup> agarose gel;<sup>7</sup>

---

<sup>1</sup> In the Supreme Court decision *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), the Court set forth factual inquiries establishing a background for determining obviousness under 35 U.S.C. 103(a). The factual inquiries include: (1) determining the scope and contents of the prior art; (2) ascertaining the differences between the prior art and the claims at issue; (3) resolving the level of ordinary skill in the pertinent art; and (4) considering objective evidence indicating obviousness or nonobviousness.

Art Unit: 1641

visualizing multimer bands by a dye in the gel;<sup>8</sup>

optionally, quantifying the dyed multimer bands.<sup>9</sup>

Shainoff does not describe "submarine" electrophoresis.

However, Bhat & Nagineni describe the use of "submarine" electrophoresis for resolving proteins (see Title).

It would have been obvious for a person of ordinary skill in the art to replace the electrophoretic protocol of Shainoff with a "submarine" method because Bhat & Nagineni discovered that the "submarine" method allows for stacking of multiple gels allowing for multiple simultaneous runs (see Abstract).

With respect to 1) and 3), Shainoff describes gels made of either "agarose" or "glyoxal agarose", or both. For example, Shainoff experimented with gels made of "regular agarose" (see p. 67, line 14, "regular agarose"). In addition, Shainoff experimented with "composite gels" made with regular agarose (see p. 72, lines 5-6 of the third paragraph, "composite of glyoxyl agarose with[...] blended with regular agarose") (paraphrasing mine).

---

<sup>2</sup> The lack of objective evidence of nonobviousness in the instant application does not suggest "the level of ordinary skill in the pertinent art" is high.

<sup>3</sup> See p. 78, Section 2.1.1.1 *Gel concentrations*, first paragraph, line 5, "separating von Willebrand factor multimers".

<sup>4</sup> See p. 66, Section 1.1 *Development of glyoxyl agarose and composites*, first paragraph, first sentence, "fibrinogen derivatives".

<sup>5</sup> See Table 1 on p. 75.

<sup>6</sup> *Id.* Examiner equates the term "homogeneous" to the antecedent term "continuous".

<sup>7</sup> See e.g., Title; see also, p. 67, line 14, "regular agarose"; see also, p. 72, lines 5-6 of the third paragraph, "composite of glyoxyl agarose with[...] blended with regular agarose"; see also, p. 74, first paragraph, last sentence, "Our focus in this work is on agarose gels with the low sieving characteristics of regular agarose, and composites".

<sup>8</sup> See p. 98, left column, Section 2.7 *General protein staining*.

<sup>9</sup> See p. 99, Section 2.8 *Mounting, photographing and scanning gels*, first paragraph, second sentence, "densitometers".

Art Unit: 1641

Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Shainoff, *Electrophoresis and direct immunoprobings on glyoxal agarose*, in ADVANCES IN ELECTROPHORESIS, Vol. 6, VCH Publishers, pp. 65-176 (1993), and Bhat & Nagineni, 170 ANAL. BIOCHEM 105 (1988), as applied to claim 16 and 24, and further in view of Perrella & Denisov, 259 METHODS ENZYMOL. 468 (1995).

Shainoff and Bhat & Nagineni describe a method for the determination of multimers as substantially described, *supra*, and incorporated herein.

Shainoff and Bhat & Nagineni do not describe a method wherein electrophoresis is carried out between 8-12°C.

However, Perrella & Denisov describe the use of temperature to modify electrophoresis (see Title).

It would have been obvious for a person of ordinary skill in the art to modify the electrophoretic protocol of Shainoff and Bhat & Nagineni by modifying temperature because Perrella & Denisov teach that the use of temperature to modify electrophoresis allows for probing of "intermediate stages of ligation" and "quaternary structural changes" (see first paragraph).

#### **(10) Response to Argument**

Appellants argue:

1. Shainoff describes immunoperoxidase-stained fibrinogen ran on glyoxal agarose in Figure 4, which is different than Appellants' claimed dye-stained fibrinogen ran on agarose (see Appeal Brief, p. 9, first and second full paragraphs).

Art Unit: 1641

2. Shainoff do not teach the claimed invention because Shainoff is a general review article teaching different electrophoresis procedures using different gels and different gel stains, which are not linked to point out the method recited in claim 16 (see Appeal Brief, paragraph bridging pp. 9-10 to p. 10, second full paragraph; see *also*, paragraph bridging pp. 11-12).
3. The cited prior art provide no motivation to use Appellants' inferior dye labels in inferior continuous gels (see Appeal Brief, p. 10, second full paragraph to p. 11, first full paragraph; see *also*, p. 12, first full paragraph).
4. Bhat & Nagineni describe an entirely different electrophoresis procedure than Appellants' claimed procedure (see Appeal Brief, p. 13, first paragraph).
5. Perrella & Denisov describe an electrophoresis procedure specifically tailored to hemoglobin and do not suggest the precise temperature range of claim 25 (see Appeal Brief, Section III).

Appellants' arguments are not persuasive.

With respect to arguments 1) and 2), Examiner acknowledges that Shainoff describes immunoperoxidase-stained fibrinogen ran on glyoxal agarose in Figure 4, which is different than Appellants' claimed dye-stained fibrinogen ran on agarose, which Shainoff also teaches can be dye-stained<sup>10</sup> and ran on agarose.<sup>11</sup> Furthermore, Examiner observes that Shainoff teaches all these things in ONE concise journal article, so there is no need for pointing out Shainoff's concepts and calling them a "disparate".

Art Unit: 1641

With respect to argument 3), Examiner is unable to locate any objective evidence from Shainoff or Bhat & Nagineni that either Shainoff or Bhat & Nagineni share Appellants' bias against dye labels and continuous gels. To the contrary, Shainoff appears to endorse both dye labels and continuous gels by describing them in his journal article in an objective, unbiased manner as viable alternatives to fractionating either von Willebrand factor<sup>12</sup> or fibrinogen.<sup>13</sup>

With respect to argument 4), the test for obviousness is not whether the structural features of either Shainoff or Bhat & Nagineni may be bodily incorporated into Applicants' invention. Rather, the test is whether the combined teachings of Shainoff or Bhat & Nagineni suggest Applicants' invention. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981). One cannot show nonobviousness by attacking the teachings of Shainoff and Bhat & Nagineni individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

With respect to argument 5), Examiner respectfully disagrees with Appellants' position that application of Perrella's & Denisov's procedure is limited to hemoglobin. In addition to hemoglobin, Perrella & Denisov appear to suggest their technique is applicable to other multimeric proteins.<sup>14</sup> Thus, persons of ordinary skill practicing Shainoff's and Bhat's electrophoresis method may find motivation to lower the electrophoresis temperature because Perrella & Denisov demonstrated the ability of lower temperatures to capture "intermediate stages of ligation" and "quaternary structural changes"<sup>15</sup> of a multimeric protein. With respect to the precise temperature range of claim 25, it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. See *In re Aller*, 105 USPQ 233 (CCPA 1955).

---

<sup>10</sup> See *supra*, note 8.

<sup>11</sup> See *supra*, note 7.

<sup>12</sup> See *supra*, note 3.

<sup>13</sup> See *supra*, note 4.

<sup>14</sup> See p. 470, first full paragraph, "Although the techniques of cryogenic quenching for the stabilization of reaction intermediates and cryogenic electrophoresis for the separation of such intermediates may find application to the study of other proteins, our experience has been limited to the study of the hemoglobin reactions."

<sup>15</sup> See first paragraph.



Art Unit: 1641

**(11) Related Proceeding(s) Appendix**

Examiner is not aware of any related appeals, interferences, or judicial proceedings affecting, directly affected by, or having a bearing on the Board's decision in the pending appeal.

Art Unit: 1641

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,

David J. Venci  
Assistant Examiner  
Art Unit 1641



Conferees:

Long V. Le  
Supervisory Patent Examiner  
Technology Center 1600



Robert Wax  
Quality Assurance Specialist  
Technology Center 1600

